Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Shattuck Labs, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
9.89
9.93
30
0.65
1.66
5.72
1
Research and development
29.2
37.5
56.6
82.9
74.3
67.2
35.3
General and administrative
5.74
9.38
18.7
21.1
19.3
19.1
17.2
Operating expenses
35
46.9
75.3
104
93.6
86.3
52.5
Operating income
-25.1
-36.9
-45.3
-103
-92
-80.6
-51.5
Interest income
1.18
0.55
0.63
1.59
4.67
5.17
2.7
Other non-operating income
1.09
0.33
0.3
1.38
4.66
5.16
2.7
Income tax
0
0
0
0
0
0
0
Net income
-24
-36.6
-45
-102
-87.3
-75.4
-48.8
EBITDA
-24.6
-36.3
-43.9
-100
-88
-76.8
-47.8
EPS, basic
-3.17
-2.36
-1.07
-2.41
-2.05
-1.49
-0.70
EPS, diluted
-3.17
-2.36
-1.07
-2.41
-2.05
-1.49
-0.70
Shares, basic (weighted)
7.56
15.5
42
42.4
42.6
50.8
69.6
Shares, diluted (weighted)
7.56
15.5
42
42.4
42.6
50.8
69.6
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
7.01
158
92.3
47.4
126
57.4
54.2
Short-term investments
32.1
178
177
114
5
Other current assets
3.36
10.2
19.5
23.3
12.6
6.23
4.41
Total current assets
42.4
346
288
185
143
79.2
82.5
Property, plant and equipment
2.44
3
9.94
17.7
13.8
9.81
6.11
Lease right-of-use assets
2.64
2.27
1.84
1.34
Other non-current assets
0.09
0.35
0.38
3.07
2.54
2.02
1.44
Total assets
45
349
299
205
160
91
91
Accounts payable
3.05
1.75
10
7.17
1.59
2.42
2.1
Accrued liabilities
0.97
1.55
3.32
3.97
3.79
2.29
2.77
Deferred revenue
12.9
7.73
0
0
0.34
Total current liabilities
20
16.8
24.6
25
11.5
8.92
7.05
Lease liabilities
0
4.2
3.41
2.51
1.58
Total liabilities
30.5
39.1
26.8
29.2
14.9
11.4
8.64
Paid-in capital
0.89
382
389
396
451
461
513
Retained earnings
-35.5
-72.1
-117
-219
-306
-382
-431
Other comprehensive income
0.05
-0.06
-0.56
-0.88
0
0
0.01
Shareholders' equity
-34.5
310
272
176
145
79.6
82.4
Total equity
-34.5
310
272
176
145
79.6
82.4
Total liabilities and equity
45
349
299
205
160
91
91
Shares outstanding
7.6
41.8
42.3
42.4
47.3
47.7
63.3
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-24
-36.6
-45
-102
-87.3
-75.4
-48.8
Depreciation and amortization
0.5
0.6
1.4
3.1
4
3.8
3.7
Stock-based compensation
0.46
1.27
5.47
6.46
6.94
9.55
7
Change in payables
1
-1.75
7.87
-2.84
-5.63
0.83
-0.32
Cash from operations
-21
-33.7
-57.1
-94.5
-81.2
-60.5
-39.9
Capital expenditures
-0.47
-0.73
-7.93
-11.6
-0.41
-0.06
-0.07
Purchases of investments
-44.3
-183
-204
-132
-79.7
-93.6
-43.4
Cash from investing
-3.59
-146
-10.4
49.4
111
-8.51
-7.89
Stock issued
0
0.23
0
48.2
44.5
Cash from financing
-0.06
331
1.93
0.17
48.6
0.79
44.6
Net change in cash
-24.6
151
-65.6
-44.9
78.2
-68.2
-3.2
Free cash flow
-21.4
-34.4
-65
-106
-81.6
-60.6
-40
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.07 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-5,579.0%
Operating income / revenue.
EBITDA margin
-5,222.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-5,257.0%
Net income / revenue.
Operating cash flow margin
-4,103.0%
Cash from operations / revenue.
Return on equity (ROE)
-24.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-23.8%
Net income / average total assets.
Return on invested capital (ROIC)
-29.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
3,932.0%
Research and development expense / revenue.
Stock-based pay / revenue
853.2%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
356.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-82.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
15.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-36.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
3.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-22.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-23.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-0.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-23.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-23.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
37.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
18.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
35.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
27.6x
Current assets / current liabilities.
Quick ratio
8.19x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
8.19x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.01
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.32
Cash from operations / diluted weighted shares.
Book value per share
$2.10
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
609x
Market cap / revenue.
P/B
2.89x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.89x
Market cap / tangible book value, when positive.
EV/Sales
546x
Enterprise value / revenue.
Earnings yield
-8.6%
Net income / market cap (the inverse of P/E).
What was Shattuck Labs, Inc.'s revenue in fiscal 2025?
Shattuck Labs, Inc. reported revenue of $1.0M for fiscal 2025, 82.5% lower than the year before.
Was Shattuck Labs, Inc. profitable in fiscal 2025?
No. It reported a net loss of $48.8M.
How much free cash flow did Shattuck Labs, Inc. generate in fiscal 2025?
Cash from operations of $39.9M minus capital expenditures of $71.0K left free cash flow of -$40.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.